168 related articles for article (PubMed ID: 27725597)
1. [Clinical manifestation and treatment of extranodal diffuse large B-cell lymphoma].
Tomita N
Rinsho Ketsueki; 2016; 57(10):1991-1999. PubMed ID: 27725597
[TBL] [Abstract][Full Text] [Related]
2. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma.
Martelli M; Ferreri AJ; Agostinelli C; Di Rocco A; Pfreundschuh M; Pileri SA
Crit Rev Oncol Hematol; 2013 Aug; 87(2):146-71. PubMed ID: 23375551
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
5. [Extranodal diffuse large B-cell lymphoma--an organotypic disease?].
Ott G; Rosenwald A
Pathologe; 2007 Feb; 28(1):29-35. PubMed ID: 17211671
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
7. Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry.
Kim MK; Bae SH; Bae YK; Kum YS; Ryoo HM; Cho HS; Lee KH; Koh SA; Lee HY; Yun SY; Choi JH; Hyun MS
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):403-8. PubMed ID: 21700526
[TBL] [Abstract][Full Text] [Related]
8. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
9. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
[TBL] [Abstract][Full Text] [Related]
11. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
12. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
[TBL] [Abstract][Full Text] [Related]
13. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
14. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
16. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
17. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
Olszewski AJ; Winer ES; Castillo JJ
Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.
Møller MB; Pedersen NT; Christensen BE
Br J Haematol; 2004 Jan; 124(2):151-9. PubMed ID: 14687024
[TBL] [Abstract][Full Text] [Related]
19. The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.
Twa DDW; Mottok A; Savage KJ; Steidl C
Blood Rev; 2018 May; 32(3):249-255. PubMed ID: 29289361
[TBL] [Abstract][Full Text] [Related]
20. Extranodal diffuse large B cell lymphoma of cutaneous follicle centre lymphoma type: a study of 24 patients with non-cutaneous primary limited stage extranodal diffuse large B cell lymphoma in support of a new concept.
Aigner F; Korol D; Schmitt AM; Kurrer MO
Histopathology; 2012 Apr; 60(5):774-84. PubMed ID: 22304695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]